JFJulia Puppin Chaves Fulber

Julia Puppin Chaves Fulber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Puppin Chaves Fulber has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Case Study

    by Laurence Dubeau-Mallette, Julia Puppin Chaves Fulber, Amine A. Kamen

  • Open Access

    Real‐Time Monitoring of In Vitro Transcription for Production of mRNA Using Raman Spectroscopy

    by Julia Puppin Chaves Fulber, Xingge Xu, Hadi El Radi, Kevin Grollier, Amine A. Kamen

    The success of COVID‐19 mRNA vaccines showcased the transformative potential of this adaptable, plug‐and‐play, and rapid response platform. Although these vaccines offer faster development and production compared to those traditionally produced in cell culture or eggs, critical manufacturing challenges remain. Notably, costly raw materials are required for in vitro transcription (IVT) and current methods for real‐time monitoring of IVT are lacking. Herein, we present simultaneous inline monitoring of ATP, CTP, GTP, UTP, and mRNA concentrations during IVT using Raman spectroscopy and partial‐least squares regression (PLS) data analysis. Model prediction performance resulted in R 2 of 0.82–0.99 and relative errors of 4%–13%, comparable to errors from reference offline assays (10%–12%). Furthermore, we analyze Raman spectral features associated with total mRNA concentration and sequence‐specific variations, demonstrating sequence‐independent prediction capability that eliminates the need for model recalibration across different products. This approach advances real‐time monitoring for mRNA manufacturing and supports the future transition toward continuous processing, automated digital twins, and Pharma 4.0 paradigms.


  • Open Access

    Preliminary Evaluation of Formulations for Stability of mRNA-LNPs Through Freeze-Thaw Stresses and Long-Term Storage

    by Maryam Youssef, Cynthia Hitti, Julia Puppin Chaves Fulber, Faizul Hussain Khan, Ayyappasamy Sudalaiyadum Perumal, Amine A. Kamen

    Ionizable lipid nanoparticles were a crucial contribution to the effective packaging and delivery of mRNA informational drugs for vaccines and therapeutic applications. However, thermal instability and the need for ultracold storage present significant challenges during distribution and administration, even during non-pandemic periods like epidemics. Ongoing efforts include engineering novel lipids or optimizing mRNA-LNP formulations with different buffers, excipients, and surfactants to enable extended storage at room temperature (RT) or refrigerated conditions (4 ˚C). Methods: In this study, six sugar-surfactant excipient combinations in tris buffer were evaluated for extending the stability of mRNA-LNPs. The experimentation included two phases of screening: first, the evaluation of six formulations under repeated freeze-thaw (−20 °C) cycles, and second, a long-term storage evaluation of the best formulations at RT, 4 °C, − 20 °C and −80 °C. LNPs were formulated with the ionizable lipids ALC-0315 or SM-102. Results: Sucrose-P188 and mannitol-F127 combinations effectively preserved physicochemical properties like encapsulation efficiency (EE), polydispersity index (PDI), and z-average (size) of mRNA-LNPs. Surfactants in the screened formulations reduced the aggregation of LNPs. Storage at −20 °C with sucrose-P188 extended LNP stability beyond ultra-low temperature requirements, showing potential for removing logistical hurdles to improve global delivery by eliminating the need for ultracold storage. Excipients in non-frozen conditions preserved the LNP quality attributes, but the RNA integrity was affected. On the other hand, mRNA degradation was minimized when frozen, but LNP quality was affected, underscoring the challenging trade-off during storage condition optimization. Conclusions: This work highlights the potential of improved formulations to preserve mRNA-LNP functionality and emphasizes the need for further systematic studies on a library of excipient and surfactant combinations, paving the way for stable storage under less stringent conditions.


  • Open Access

    Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing

    by Maryam Youssef, Cynthia Hitti, Julia Puppin Chaves Fulber, Amine A. Kamen

    Recent advances and discoveries in the structure and role of mRNA as well as novel lipid-based delivery modalities have enabled the advancement of mRNA therapeutics into the clinical trial space. The manufacturing of these products is relatively simple and eliminates many of the challenges associated with cell culture production of viral delivery systems for gene and cell therapy applications, allowing rapid production of mRNA for personalized treatments, cancer therapies, protein replacement and gene editing. The success of mRNA vaccines during the COVID-19 pandemic highlighted the immense potential of this technology as a vaccination platform, but there are still particular challenges to establish mRNA as a widespread therapeutic tool. Immunostimulatory byproducts can pose a barrier for chronic treatments and different production scales may need to be considered for these applications. Moreover, long-term storage of mRNA products is notoriously difficult. This review provides a detailed overview of the manufacturing steps for mRNA therapeutics, including sequence design, DNA template preparation, mRNA production and formulation, while identifying the challenges remaining in the dose requirements, long-term storage and immunotolerance of the product.


  • Open Access

    Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine

    by Zeyu Yang, Barbara Cristina Martins Fernandes Paes, Julia Puppin Chaves Fulber, Michelle Yen Tran, Omar Farnós, Amine A. Kamen

    The administration of viral vectored vaccines remains one of the most effective ways to respond to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. However, pre-existing immunity to the viral vector hinders its potency, resulting in a limited choice of viral vectors. Moreover, the basic batch mode of manufacturing vectored vaccines does not allow one to cost-effectively meet the global demand for billions of doses per year. To date, the exposure of humans to VSV infection has been limited. Therefore, a recombinant vesicular stomatitis virus (rVSV), which expresses the spike protein of SARS-CoV-2, was selected as the vector. To determine the operating upstream process conditions for the most effective production of an rVSV-SARS-CoV-2 candidate vaccine, a set of critical process parameters was evaluated in an Ambr 250 modular system, whereas in the downstream process, a streamlined process that included DNase treatment, clarification, and a membrane-based anion exchange chromatography was developed. The design of the experiment was performed with the aim to obtain the optimal conditions for the chromatography step. Additionally, a continuous mode manufacturing process integrating upstream and downstream steps was evaluated. rVSV-SARS-CoV-2 was continuously harvested from the perfusion bioreactor and purified by membrane chromatography in three columns that were operated sequentially under a counter-current mode. Compared with the batch mode, the continuous mode of operation had a 2.55-fold increase in space–time yield and a reduction in the processing time by half. The integrated continuous manufacturing process provides a reference for the efficient production of other viral vectored vaccines.


  • Open Access

    Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use

    by Julia P. C. Fulber, Amine A. Kamen

    The COVID-19 pandemic has highlighted the need for efficient vaccine platforms that can rapidly be developed and manufactured on a large scale to immunize the population against emerging viruses. Viral-vectored vaccines are prominent vaccine platforms that have been approved for use against the Ebola virus and SARS-CoV-2. The Newcastle Disease Virus is a promising viral vector, as an avian paramyxovirus that infects poultry but is safe for use in humans and other animals. NDV has been extensively studied not only as an oncolytic virus but also a vector for human and veterinary vaccines, with currently ongoing clinical trials for use against SARS-CoV-2. However, there is a gap in NDV research when it comes to process development and scalable manufacturing, which are critical for future approved vaccines. In this review, we summarize the advantages of NDV as a viral vector, describe the steps and limitations to generating recombinant NDV constructs, review the advances in human and veterinary vaccine candidates in pre-clinical and clinical tests, and elaborate on production in embryonated chicken eggs and cell culture. Mainly, we discuss the existing data on NDV propagation from a process development perspective and provide prospects for the next steps necessary to potentially achieve large-scale NDV-vectored vaccine manufacturing.


  • Open Access

    Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures

    by Julia Puppin Chaves Fulber, Omar Farnós, Sascha Kiesslich, Zeyu Yang, Shantoshini Dash, Leonardo Susta, Sarah K. Wootton, Amine A. Kamen

    The ongoing COVID-19 pandemic drew global attention to infectious diseases, attracting numerous resources for development of pandemic preparedness plans and vaccine platforms—technologies with robust manufacturing processes that can quickly be pivoted to target emerging diseases. Newcastle Disease Virus (NDV) has been studied as a viral vector for human and veterinary vaccines, but its production relies heavily on embryonated chicken eggs, with very few studies producing NDV in cell culture. Here, NDV is produced in suspension Vero cells, and analytical assays (TCID50 and ddPCR) are developed to quantify infectious and total viral titer. NDV-GFP and NDV-FLS (SARS-CoV-2 full-length spike protein) constructs were adapted to replicate in Vero and HEK293 suspension cultures using serum-free media, while fine-tuning parameters such as MOI, temperature, and trypsin concentration. Shake flask productions with Vero cells resulted in infectious titers of 1.07 × 108 TCID50/mL for NDV-GFP and 1.33 × 108 TCID50/mL for NDV-FLS. Production in 1 L batch bioreactors also resulted in high titers in culture supernatants, reaching 2.37 × 108 TCID50/mL for NDV-GFP and 3.16 × 107 TCID50/mL for NDV-FLS. This shows effective NDV production in cell culture, building the basis for a scalable vectored-vaccine manufacturing process that can be applied to different targets.